Drug intelligence / Profile preview

CU71

Development stage: Discontinued
Lead developer: Curacle
Modality: Small Molecules

Overview

CU71 is a small molecule drug candidate developed by Curacle. It has been investigated primarily for the treatment of Alzheimer's disease, where preclinical results presented by Curacle showed improved memory and cognitive function in comparison to donepezil, a standard dementia therapy. Although previously in development for Alzheimer's disease and possibly other indications, recent information indicates that its highest R&D status is "discontinued" and it is no longer in active clinical development.

Beyond the preview

Go deeper on CU71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CU71.

Explore the full profile